Niemann-pick disease type C: Induced pluripotent stem cell-derived neuronal cells for modeling neural disease and evaluating drug efficacy

Journal of Biomolecular Screening

Volumn 19, Issue 8, 2014, Pages 1164-1173

  Yu, Daozhan ^a   Swaroop, Manju ^b   Wang, Mengqiao ^b   Baxa, Ulrich ^c   Yang, Rongze ^a   Yan, Yiping ^d   Coksaygan, Turhan ^a   Detolla, Louis ^d   Marugan, Juan J ^b   Austin, Christopher P ^b   McKew, John C ^b   Gong, Da Wei ^a,e   Zheng, Wei ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Life Technologies Inc   (United States)

^e BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

cyclodextrin; differentiated neurons; drug combination therapy; induced pluripotent stem cells; Niemann Pick disease type C; NPC1; tocopherol

Indexed keywords

CHOLESTEROL; CYCLODEXTRIN; DELTA-TOCOPHEROL; TOCOPHEROL;

CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; LYSOSOME; METABOLISM; NERVE CELL; NEURAL STEM CELL; NIEMANN-PICK DISEASE, TYPE C; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES;

CELL DIFFERENTIATION; CELLS, CULTURED; CHOLESTEROL; CYCLODEXTRINS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LYSOSOMES; NEURAL STEM CELLS; NEURONS; NIEMANN-PICK DISEASE, TYPE C; TOCOPHEROLS;

EID: 84905586567     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114537378     Document Type: Article

References (35)

1. Vanier M. T.. Niemann-Pick Disease Type C. Orphanet J. Rare Dis. 2010 ; 5: 16
2. Chen F. W., Li C., Ioannou Y. A.. Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis. PLoS One. 2010 ; 5: e15054
3. Davidson C. D., Ali N. F., Micsenyi M. C., et al. Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression. PLoS One. 2009 ; 4: e6951
4. Liu B., Turley S. D., Burns D. K., et al. Reversal of Defective Lysosomal Transport in NPC Disease Ameliorates Liver Dysfunction and Neurodegeneration in the npc1-/- Mouse. Proc. Natl. Acad. Sci. USA. 2009 ; 106: 2377-2382
5. Rosenbaum A. I., Zhang G., Warren J. D., et al. Endocytosis of Beta-Cyclodextrins Is Responsible for Cholesterol Reduction in Niemann-Pick Type C Mutant Cells. Proc. Natl. Acad. Sci. USA. 2010 ; 107: 5477-5482
6. Peake K. B., Vance J. E.. Normalization of Cholesterol Homeostasis by 2-Hydroxypropyl-Beta-Cyclodextrin in Neurons and Glia from Niemann-Pick C1 (NPC1)-Deficient Mice. J. Biol. Chem. 2012 ; 287: 9290-9298
7. Patterson M. C., Vecchio D., Prady H., et al. Miglustat for Treatment of Niemann-Pick C Disease: A Randomised Controlled Study. Lancet Neurol. 2007 ; 6: 765-772
8. Lloyd-Evans E., Morgan A. J., He X., et al. Niemann-Pick Disease Type C1 Is a Sphingosine Storage Disease That Causes Deregulation of Lysosomal Calcium. Nat. Med. 2008 ; 14: 1247-1255
9. Pipalia N. H., Cosner C. C., Huang A., et al. Histone deacetylase Inhibitor Treatment Dramatically Reduces Cholesterol Accumulation in Niemann-Pick Type C1 Mutant Human Fibroblasts. Proc. Natl. Acad. Sci. USA. 2011 ; 108: 5620-5625
10. Madra M., Sturley S. L.. Niemann-Pick Type C Pathogenesis and Treatment: From Statins to Sugars. Clin. Lipidol. 2010 ; 5: 387-395
11. Wehrmann Z. T., Hulett T. W., Huegel K. L., et al. Quantitative Comparison of the Efficacy of Various Compounds in Lowering Intracellular Cholesterol Levels in Niemann-Pick Type C Fibroblasts. PLoS One. 2012 ; 7: e48561
12. Matsuo M., Togawa M., Hirabaru K., et al. Effects of Cyclodextrin in Two Patients with Niemann-Pick Type C Disease. Mol. Genet. Metab. 2013 ; 108: 76-81
13. Xu M., Liu K., Swaroop M., et al. δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. J. Biol. Chem. 2012 ; 287: 39349-39360
14. Robinton D. A., Daley G. Q.. The Promise of Induced Pluripotent Stem Cells in Research and Therapy. Nature. 2012 ; 481: 295-305
15. Zhang M., Luo G., Zhou Y., et al. Phenotypic Screens Targeting Neurodegenerative Diseases. J. Biomol. Screen. 2014 ; 19: 1-16
16. Kim K. J., Wang J., Xu X., et al. A Chemical Genomics Screen to Discover Genes That Modulate Neural Stem Cell Differentiation. J. Biomol. Screen. 2012 ; 17: 129-139
17. Zhao W. N., Cheng C., Theriault K. M., et al. A High-Throughput Screen for Wnt/Beta-Catenin Signaling Pathway Modulators in Human iPSC-Derived Neural Progenitors. J. Biomol. Screen. 2012 ; 17: 1252-1263
18. Lee G., Ramirez C. N., Kim H., et al. Large-Scale Screening Using Familial Dysautonomia Induced Pluripotent Stem Cells Identifies Compounds That Rescue IKBKAP Expression. Nat. Biotechnol. 2012 ; 30: 1244-1248
19. McLaren D., Gorba T., Marguerie de Rotrou A., et al. Automated Large-Scale Culture and Medium-Throughput Chemical Screen for Modulators of Proliferation and Viability of Human Induced Pluripotent Stem Cell-Derived Neuroepithelial-Like Stem Cells. J. Biomol. Screen. 2013 ; 18: 258-268
20. Swaroop M., Thorne N., Rao M. S., et al. Evaluation of Cholesterol Reduction Activity of Methyl-Beta-Cyclodextrin Using Differentiated Human Neurons and Astrocytes. J. Biomol. Screen. 2012 ; 17: 1243-1251
21. Xu M., Liu K., Swaroop M., et al. A Phenotypic Compound Screening Assay for Lysosomal Storage Diseases. J. Biomol. Screen. 2014 ; 19: 168-175
22. Lieu P. T., Fontes A., Vemuri M. C., et al. Generation of Induced Pluripotent Stem Cells with CytoTune, a Non-Integrating Sendai Virus. Methods Mol. Biol. 2013 ; 997: 45-56
23. Lee G., Papapetrou E. P., Kim H., et al. Modelling Pathogenesis and Treatment of Familial Dysautonomia Using Patient-Specific iPSCs. Nature. 2009 ; 461: 402-406
24. Agarwal S., Loh Y. H., McLoughlin E. M., et al. Telomere Elongation in Induced Pluripotent Stem Cells from Dyskeratosis Congenita Patients. Nature. 2010 ; 464: 292-296
25. Huang H. P., Chen P. H., Hwu W. L., et al. Human Pompe Disease-Induced Pluripotent Stem Cells for Pathogenesis Modeling, Drug Testing and Disease Marker Identification. Hum. Mol. Genet. 2011 ; 20: 4851-4864
26. Tiscornia G., Vivas E. L., Matalonga L., et al. Neuronopathic Gaucher's Disease: Induced Pluripotent Stem Cells for Disease Modelling and Testing Chaperone Activity of Small Compounds. Hum. Mol. Genet. 2013 ; 22: 633-645
27. Hamasaki M., Hashizume Y., Yamada Y., et al. Pathogenic Mutation of ALK2 Inhibits Induced Pluripotent Stem Cell Reprogramming and Maintenance: Mechanisms of Reprogramming and Strategy for Drug Identification. Stem Cells. 2012 ; 30: 2437-2349
28. Panicker L. M., Miller D., Park T. S., et al. Induced Pluripotent Stem Cell Model Recapitulates Pathologic Hallmarks of Gaucher Disease. Proc. Natl. Acad. Sci. USA. 2012 ; 109: 18054-18059
29. Tolar J., Park I. H., Xia L., et al. Hematopoietic Differentiation of Induced Pluripotent Stem Cells from Patients with Mucopolysaccharidosis Type I (Hurler Syndrome). Blood. 2011 ; 117: 839-847
30. Lemonnier T., Blanchard S., Toli D., et al. Modeling Neuronal Defects Associated with a Lysosomal Disorder Using Patient-Derived Induced Pluripotent Stem Cells. Hum. Mol. Genet. 2011 ; 20: 3653-3666
31. Trilck M., Hubner R., Seibler P., et al. Niemann-Pick Type C1 Patient-Specific Induced Pluripotent Stem Cells Display Disease Specific Hallmarks. Orphanet J. Rare Dis. 2013 ; 8: 144
32. Bergamin N., Dardis A., Beltrami A., et al. A Human Neuronal Model of Niemann Pick C Disease Developed from Stem Cells Isolated from Patient's Skin. Orphanet J. Rare Dis. 2013 ; 8: 34
33. Rodriguez-Pascau L., Coll M. J., Casas J., et al. Generation of a Human Neuronal Stable Cell Model for Niemann-Pick C Disease by RNA Interference. JIMD Rep. 2012 ; 4: 29-37
34. Ordonez M. P., Roberts E. A., Kidwell C. U., et al. Disruption and Therapeutic Rescue of Autophagy in a Human Neuronal Model of Niemann Pick Type C1. Hum. Mol. Genet. 2012 ; 21: 2651-2662
35. Zheng W., Thorne N., McKew J. C.. Phenotypic Screens as a Renewed Approach for Drug Discovery. Drug Discov. Today. 2013 ; 18: 1067-1073